You are completely misinterpretting the ANN - its not that it CAN'T move forward. They dont want to SPEND any more money moving forward on it as the single test and the imminent removal of the commons list requirement is ending. I dont understand how you are missing that ?
The money will go towards the multiplex test, the single test if there is demand for it, can sell post June 2023 when the Commons List requirement is abolished....
Anyway getting tired responding.
@Artvaldaley re-reading yes - there is an over emphasis that this is amazing news,when in fact it shouldnt have happened in the first place...
Ann: European RAT Clinical Trial Halted to Refocus Initiatives, page-144
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
-0.002(8.33%) |
Mkt cap ! $54.31M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.4¢ | 2.2¢ | $12.59K | 542.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 487271 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 200000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| ADO (ASX) Chart |